BioArctic
Tracked across 11 events · 79 articles · First seen Apr 21, 2026 · Last active Aug 19, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: BioArctic held its Annual General Meeting, making several key resolutions including dividend payment, board re-elections, and approval of an incentive program, which directly impacts its corporate governance and shareholder value.
May 28, 2026 · 9 articles
Business
Impact: BioArctic issued 5,000 Class B shares to participants in its stock option program, increasing its total number of shares and votes.
May 29, 2026 · 6 articles
Business
Impact: BioArctic receives royalties from Leqembi sales; Q2 2026 royalty of SEK 179 million represents 10% growth, boosting revenue outlook.
Jul 29, 2026 · 6 articles
Business
BioArctic announced it will publish its second quarter report for April-June 2026 on August 26, 2026, at 8:00 a.m. CEST. The company invited investors, analysts, and media to a webcast and teleconference at 9:30 a.m.…
Impact: BioArctic is the company issuing the Q2 report and hosting the investor presentation. The event is routine and does not change its outlook.
Aug 19, 2026 · 6 articles
Business
On August 19, 2026, BioArctic and Bicara Therapeutics announced a research collaboration agreement to develop a novel antibody-based treatment for glioblastoma, an aggressive brain cancer. The collaboration combines BioArctic's BrainTransporter technology with Mesenkia's KITAIbodies platform,…
Impact: BioArctic is a key party, contributing its BrainTransporter technology and leading drug candidate generation. The collaboration expands its pipeline into oncology, potentially enhancing its growth prospects.
Aug 19, 2026 · 6 articles
Business
Impact: BioArctic, in collaboration with Eisai, developed Lecanemab and is set to receive approximately SEK 880 million in royalties from the projected sales, indicating a positive financial outlook for the company.
May 15, 2026 · 6 articles
Business
Impact: As the inventor of Lecanemab and a partner in its development and commercialization, BioArctic stands to benefit significantly from the projected sales, receiving royalties and milestone payments. This event positively impacts its financial outlook.
May 25, 2026 · 7 articles
Tech
A nationwide Swedish observational study from Karolinska Institute, published in the European Heart Journal, found that patients with both atrial fibrillation and Alzheimer's disease who were treated with newer oral anticoagulants (NOACs) experienced a significantly…
Impact: Greta Duréel has consulted for BioArctic, but no direct impact from this study.
Aug 12, 2026 · 6 articles
90
BioArctic signed research collaboration Bicara TherapeuticsBioArctic Mesenkia...
ERGEN INTELLIGENCE
Track BioArctic live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard